Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Oct. 18 to 22, 2021. This […]
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Oct. 18 to 22, 2021. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
BNT162b2 Effectively Prevents Pediatric COVID-19 Hospitalization
FRIDAY, Oct. 22, 2021 (HealthDay News) — For children and adolescents aged 12 to 18 years, two doses of the Pfizer-BioNTech vaccine (BNT162b2) are highly effective for preventing COVID-19 hospitalization, according to research published in the Oct. 22 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Michigan Data Show Routine Vaccinations Plummeted in Early Pandemic
FRIDAY, Oct. 22, 2021 (HealthDay News) — There were drops in routine vaccinations among both children and adults during the COVID-19 pandemic, according to a study published online Oct. 7 in the American Journal of Public Health.
Delta Variant Subtype on Rise in United Kingdom
FRIDAY, Oct. 22, 2021 (HealthDay News) — A subtype of the delta variant of the coronavirus is causing a growing number of infections in the United Kingdom and is being closely monitored there and in other countries.
Pfizer Says Lower Dose of Its COVID-19 Vaccine Protects Younger Children
FRIDAY, Oct. 22, 2021 (HealthDay News) — A lower dose of the Pfizer COVID-19 vaccine is 90.7 percent effective in preventing symptomatic COVID-19 in children aged 5 to 11 years, according to new clinical trial data from the company.
CDC Signs Off on Moderna, J&J Boosters, Backs Mix ‘n’ Match Shots
FRIDAY, Oct. 22, 2021 (HealthDay News) — The U.S. Centers for Disease Control and Prevention on Thursday gave its blessing to booster shots of the Moderna and Johnson & Johnson COVID-19 vaccines for tens of millions of Americans.
BNT162b2 Highly Effective Against Delta Variant in Teens
FRIDAY, Oct. 22, 2021 (HealthDay News) — The BNT162b2 vaccine is highly effective against the delta variant among adolescents aged 12 to 18 years, according to a letter to the editor published online Oct. 20 in the New England Journal of Medicine.
mRNA Vaccine More Effective Booster to ChAdOx1 nCoV-19
FRIDAY, Oct. 22, 2021 (HealthDay News) — Use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is more effective than homologous ChAdOx1 nCoV-19/ChAdOx1 nCoV-19 prime-boost vaccination, according to a study published online Oct. 17 in The Lancet Regional Health: Europe.
Geriatrics-Focused Risk Factors ID’d for COVID-19 Death
FRIDAY, Oct. 22, 2021 (HealthDay News) — Factors other than age predict mortality in older adults hospitalized with COVID-19, according to a study published online Oct. 14 in BMC Geriatrics.
Poisoning Related to Ivermectin Exposure for COVID-19 Described
Trends Reported in Vaccination Coverage for Adolescents for 2025 
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season 
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
Social Media Warnings Could Discourage Use Among Teens, Young Adults 
Digital Behavioral Health Game Reduces Depressive Symptoms in Teens .jpeg)
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay 
Reinitiating Obesity Meds After Bariatric Surgery Tied to Greater One-Year Weight Loss in Youths 
.jpeg)
